美國著名戴夫 DAVE 深 滬
已收盤 02-06 16:00:00 美东时间
183.22
+27.300
+17.51%
華盛通- 最 高185.85
- 今 開175.73
- 成交量 80.08万股
- 最 低 170.11
- 昨 收 155.92
- 總市值 24.74亿
- 52周最高 286.45
- 市盈率 靜 43.76
- 換手率 5.93%
- 52周最低 65.46
- 委 比 -6.80%
- 總股本 1350.41万
- 歷史最高 1110.912
- 量 比 1.38
- 振 幅 10.09%
- 歷史最低 7.73
- 每 手 1
- 風險率 55.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | 美国著名戴夫 2025财年Q4营收1.64亿美元，同比增长62.4%；归母净利润0.73亿美元，同比增长121.2%
华盛资讯2月6日讯，美国著名戴夫公布2025财年Q4业绩，公司Q4营收1.64亿美元，同比增长62.4%，归母净利润0.73亿美元，同比增长121.2%。
02-06 16:17
Dave shares are trading higher after the company reported preliminary Q4 financial results.
Dave shares are trading higher after the company reported preliminary Q4 financ...
02-06 05:46
Dave Reports Q4 Preliminary Net Revenue $164M, FY25 Revenue $554M
Dave Inc. ("Dave" or the "Company") (Nasdaq: DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The
02-06 05:32
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
Dave Inc. shares are trading higher after the company reported Q3 earnings and revenue above estimates and raised its FY2025 sales guidance above expectations.
Dave Inc. shares are trading higher after the company reported Q3 earnings and ...
2025-11-04 20:34
Dave Raises FY2025 Sales Guidance from $505.000M-$515.000M to $544.000M-$547.000M vs $511.100M Est
Dave (NASDAQ:DAVE) raises FY2025 sales outlook from $505.000 million-$515.000 million to $544.000 million-$547.000 million vs $511.100 million estimate.
2025-11-04 20:31
Dave Q3 Adj. EPS $4.24 Beats $1.82 Estimate, Sales $150.800M Beat $132.843M Estimate
Dave (NASDAQ:DAVE) reported quarterly earnings of $4.24 per share which beat the analyst consensus estimate of $1.82 by 132.97 percent. This is a 180.79 percent increase over earnings of $1.51 per share from the same
2025-11-04 20:29
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
Barrington Research Maintains Outperform on Dave, Maintains $290 Price Target
Barrington Research analyst Gary Prestopino maintains Dave (NASDAQ:DAVE) with a Outperform and maintains $290 price target.
2025-11-03 21:03
